Literature DB >> 33998867

The CB1 Receptor Differentially Regulates IFN-γ Production In Vitro and in Experimental Autoimmune Encephalomyelitis.

James M Nichols1, Barbara L F Kaplan1.   

Abstract

Introduction: Activation of the peripheral immune system and the infiltration of immune cells into the central nervous system are both key features of the experimental autoimmune encephalomyelitis (EAE) model. By exploring how the endocannabinoid system works to modulate this response, we can better understand how exogenous cannabinoids, such as THC, might be used to modulate the immune responses of multiple sclerosis patients. Materials and
Methods: In this study, we examined the role of the CB1 receptor in IFN-γ and IL-17A production in the EAE model and in vitro stimulations of naive splenocytes using Cnr1-/- mice and wild-type (WT) littermates. We also introduce a novel method of scoring spinal cord histological sections to show the differences in disease severity between Cnr1-/- and WT mice with EAE.
Results: Clinical scores of Cnr1-/-/EAE and WT/EAE mice showed more severe disease progression in Cnr1-/- mice, which was confirmed using our new histological scoring method. In the peripheral immune system, IFN-γ production by restimulated splenocytes from Cnr1-/-/EAE mice, compared with WT/EAE mice, was increased and the primary source of IFN-γ was a CD3- cell population; however, IFN-γ production by Cnr1-/- splenocytes was decreased compared with WT splenocytes when the primary source of IFN-γ was CD3+ T cells in cultures from naive mice stimulated by either anti-CD3/anti-CD28 antibodies or Staphylococcal superantigens.
Conclusion: These findings suggest a duality to the CB1 receptor's effects on the peripheral immune response, which varies based on the specific cell types stimulated. Knowledge of the complex nature of a receptor is an important part of determining its potential usefulness as a therapeutic target, and these findings further define the role of CB1 in IFN-γ responses.

Entities:  

Keywords:  CB1 receptor; IFN-γ; experimental autoimmune encephalomyelitis; multiple sclerosis

Mesh:

Substances:

Year:  2020        PMID: 33998867      PMCID: PMC8380800          DOI: 10.1089/can.2020.0046

Source DB:  PubMed          Journal:  Cannabis Cannabinoid Res        ISSN: 2378-8763


  35 in total

Review 1.  Exotoxins of Staphylococcus aureus.

Authors:  M M Dinges; P M Orwin; P M Schlievert
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

2.  Sex ratio of multiple sclerosis and clinical phenotype.

Authors:  S V Ramagopalan; J K Byrnes; S-M Orton; D A Dyment; C Guimond; I M Yee; G C Ebers; A D Sadovnick
Journal:  Eur J Neurol       Date:  2009-11-24       Impact factor: 6.089

Review 3.  Multiple sclerosis - a review.

Authors:  R Dobson; G Giovannoni
Journal:  Eur J Neurol       Date:  2018-11-18       Impact factor: 6.089

4.  Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity.

Authors:  Paul Browne; Dhia Chandraratna; Ceri Angood; Helen Tremlett; Chris Baker; Bruce V Taylor; Alan J Thompson
Journal:  Neurology       Date:  2014-09-09       Impact factor: 9.910

Review 5.  T cells in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  J M Fletcher; S J Lalor; C M Sweeney; N Tubridy; K H G Mills
Journal:  Clin Exp Immunol       Date:  2010-10       Impact factor: 4.330

Review 6.  The effects of cannabinoids on the brain.

Authors:  A Ameri
Journal:  Prog Neurobiol       Date:  1999-07       Impact factor: 11.685

7.  Incidence of multiple sclerosis in the United Kingdom : findings from a population-based cohort.

Authors:  A Alonso; S S Jick; M J Olek; M A Hernán
Journal:  J Neurol       Date:  2007-10-01       Impact factor: 4.849

8.  Clinical experiences with cannabinoids in spasticity management in multiple sclerosis.

Authors:  L Lorente Fernández; E Monte Boquet; F Pérez-Miralles; I Gil Gómez; M Escutia Roig; I Boscá Blasco; J L Poveda Andrés; B Casanova-Estruch
Journal:  Neurologia       Date:  2013-09-10       Impact factor: 3.109

9.  Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors.

Authors:  G Pryce; D Baker
Journal:  Br J Pharmacol       Date:  2007-01-15       Impact factor: 8.739

10.  Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.

Authors:  John Zajicek; Patrick Fox; Hilary Sanders; David Wright; Jane Vickery; Andrew Nunn; Alan Thompson
Journal:  Lancet       Date:  2003-11-08       Impact factor: 79.321

View more
  1 in total

1.  Anti-inflammatory effects of recreational marijuana in virally suppressed youth with HIV-1 are reversed by use of tobacco products in combination with marijuana.

Authors:  John W Sleasman; Maureen M Goodenow; Li Yin; Ashok R Dinasarapu; Samiksha A Borkar; Kai-Fen Chang; Kristina De Paris; Julie J Kim-Chang
Journal:  Retrovirology       Date:  2022-05-31       Impact factor: 3.768

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.